Graybug seeks alternative options for eye drugs; RA-backed epilepsy outfit secures $40M Series C
Graybug Vision is in search of a new home about 21 months after landing on the Nasdaq. The ocular disease-focused biotech has seen its stock …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
